Bardoloxone methyl may curb kidney disease in type 2 diabetes

06/27/2011 | United Press International · WebMD

Bardoxolone methyl-treated patients with type 2 diabetes had better glomerular filtration rates, a measure of kidney function, compared with those who took a placebo, a study in The New England Journal of Medicine found. Researchers hope the antioxidant drug will delay or prevent the need for dialysis in patients with kidney disease.

View Full Article in:

United Press International · WebMD

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA